180 related articles for article (PubMed ID: 29474119)
1. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.
Bachhuber MA; Thompson C; Prybylowski A; Benitez J; Mazzella S; Barclay D
Subst Abus; 2018; 39(2):167-172. PubMed ID: 29474119
[TBL] [Abstract][Full Text] [Related]
2. Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018.
Weinstein LC; Iqbal Q; Cunningham A; Debates R; Landistratis G; Doggett P; Silverio A
Am J Public Health; 2020 Apr; 110(4):580-586. PubMed ID: 32078355
[No Abstract] [Full Text] [Related]
3. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
Riggins DP; Cunningham CO; Ning Y; Fox AD
Subst Abus; 2017; 38(3):297-302. PubMed ID: 27715904
[TBL] [Abstract][Full Text] [Related]
4. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.
Shah PA; Sohler NL; López C; Fox AD; Cunningham CO
J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929
[TBL] [Abstract][Full Text] [Related]
5. A novel community-based buprenorphine program: client description and initial outcomes.
Daniels AM; Salisbury-Afshar E; Hoffberg A; Agus D; Fingerhood MI
J Addict Med; 2014; 8(1):40-6. PubMed ID: 24394496
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
7. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
Campbell MD; Kolodner G; Spencer RA; DuPont RL
J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
[TBL] [Abstract][Full Text] [Related]
8. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington.
Hood JE; Banta-Green CJ; Duchin JS; Breuner J; Dell W; Finegood B; Glick SN; Hamblin M; Holcomb S; Mosse D; Oliphant-Wells T; Shim MM
Subst Abus; 2020; 41(3):356-364. PubMed ID: 31403907
[No Abstract] [Full Text] [Related]
9. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.
Monico LB; Gryczynski J; Mitchell SG; Schwartz RP; O'Grady KE; Jaffe JH
J Subst Abuse Treat; 2015 Oct; 57():89-95. PubMed ID: 25986647
[TBL] [Abstract][Full Text] [Related]
11. Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes.
Jakubowski A; Norton BL; Hayes BT; Gibson BE; Fitzsimmons C; Stern LS; Ramirez F; Guzman M; Spratt S; Marcus P; Fox AD
J Addict Med; 2022 Jul-Aug 01; 16(4):447-453. PubMed ID: 34775441
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder.
Lopian KM; Chebolu E; Kulak JA; Kahn LS; Blondell RD
J Subst Abuse Treat; 2019 Feb; 97():1-6. PubMed ID: 30577894
[TBL] [Abstract][Full Text] [Related]
13. Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment.
Hill K; Nussdorf L; Mount JD; Silk R; Gross C; Sternberg D; Bijole P; Jones M; Kier R; Mccullough D; Mathur P; Kottilil S; Masur H; Kattakuzhy S; Rosenthal ES
J Addict Med; 2022 Jan-Feb 01; 16(1):10-17. PubMed ID: 33560694
[TBL] [Abstract][Full Text] [Related]
14. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.
Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO
J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666
[TBL] [Abstract][Full Text] [Related]
15. Engagement and Substance Dependence in a Primary Care-Based Addiction Treatment Program for People Infected with HIV and People at High-Risk for HIV Infection.
Walley AY; Palmisano J; Sorensen-Alawad A; Chaisson C; Raj A; Samet JH; Drainoni ML
J Subst Abuse Treat; 2015 Dec; 59():59-66. PubMed ID: 26298399
[TBL] [Abstract][Full Text] [Related]
16. Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.
Wakeman SE; Chang Y; Regan S; Yu L; Flood J; Metlay J; Rigotti N
J Addict Med; 2019; 13(4):253-257. PubMed ID: 30550392
[TBL] [Abstract][Full Text] [Related]
17. The stepped treatment engagement protocol for homeless, needle exchange heroin-dependent patients.
Tringale R; Subica AM; Danielian A; Kaplan C
J Addict Med; 2015; 9(2):163-4. PubMed ID: 25807454
[No Abstract] [Full Text] [Related]
18. Treating homeless opioid dependent patients with buprenorphine in an office-based setting.
Alford DP; LaBelle CT; Richardson JM; O'Connell JJ; Hohl CA; Cheng DM; Samet JH
J Gen Intern Med; 2007 Feb; 22(2):171-6. PubMed ID: 17356982
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients.
Aalto M; Visapää JP; Halme JT; Fabritius C; Salaspuro M
Nord J Psychiatry; 2011 Sep; 65(4):238-43. PubMed ID: 21047194
[TBL] [Abstract][Full Text] [Related]
20. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
